<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04490902</url>
  </required_header>
  <id_info>
    <org_study_id>2020KYPJ111</org_study_id>
    <nct_id>NCT04490902</nct_id>
  </id_info>
  <brief_title>Clinical Study on the Treatment of Mixed Component Cornea for High Risk Keratoplasty</brief_title>
  <official_title>Suppression of Graft Rejection Using Mixed Component Cornea in the High-risk Keratoplasty，A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongshan Ophthalmic Center, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongshan Ophthalmic Center, Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Because of the immunologically privileged nature of the cornea, the graft rejection rate is&#xD;
      less than 10% for low-risk keratoplasty. But when the cornea performed 2 or more quadrants of&#xD;
      corneal neovascularization after ocular trauma or infection, the graft rejection rate is more&#xD;
      than 65%, it is called high-risk keratoplasty.&#xD;
&#xD;
      This study will observe the graft survival of high-risk corneal transplantation using mixed&#xD;
      component cornea from different donors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ocular trauma or infection lead to corneal limbal stem cell deficiency and central corneal&#xD;
      opacification which could only be treated by central penetrating keratoplasty and limbal&#xD;
      transplantation, but the rejection rate is very high. In clinical, we found that limbal&#xD;
      transplantation combined with central penetrating keratoplasty from different donors can keep&#xD;
      the graft transparent for a long time, this result also be found in organ transplantation,&#xD;
      multiple donor organ transplantation could reduce rejection risk in liver and kidney&#xD;
      transplantation. Therefore, it is speculated that there are different MHC antigens from&#xD;
      different donors, which cause different reactions after transplantation. Because there are a&#xD;
      large number of Langerhans cells， abundant blood vessels and lymphatic in the limbal, so the&#xD;
      rejection occurs early and severely. Continuous and intense limbal rejection leads to the&#xD;
      depletion of recipient T cells, lead to the immune tolerance of another donor's central&#xD;
      corneal tissue. In this project, central penetrating keratoplasty and limbal transplantation&#xD;
      from different donors will be carried out and the graft survival of high-risk corneal&#xD;
      transplantation will be observed in clinical, to find a new method for high-risk corneal&#xD;
      transplant patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of corneal graft rejection at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>The rejection index of corneal transplantation will be observed by slit lamp after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes of best corrected visual acuity</measure>
    <time_frame>Before surgery, 1 week, 1 month, 3 months, 6 months, 12 months</time_frame>
    <description>Best corrected visual acuity in different point will be compared with preoperative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of corneal thickness depth</measure>
    <time_frame>baseline (Before surgery), 1 week, 1 month, 3 months, 6 months, 12 months</time_frame>
    <description>Corneal thickness depth will be measured by anterior segmental OCT and compared with preoperative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reconstruction of corneal limbal</measure>
    <time_frame>baseline (Before surgery), 1 week, 1 month, 3 months, 6 months, 12 months</time_frame>
    <description>Confocal microscopy will be used to define whether the structure of corneal limbal has reconstructed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial Cell Density</measure>
    <time_frame>baseline (Before surgery), 1 week, 1 month, 3 months, 6 months, 12 months</time_frame>
    <description>Endothelial Cell Density will be measured by specular microscope to evaluate the loss of endothelial cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of presence of goblet cells containing conjunctival epithelium on the corneal surface by impression cytology</measure>
    <time_frame>baseline (Before surgery), 1 week, 1 month, 3 months, 6 months, 12 months</time_frame>
    <description>Detects whether conjunctival epithelial and goblet cells have invaded the corneal surface by impression cytology, to observe the reconstruction of limbal function</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Before surgery, 1 week, 1 month, 3 months, 6 months, 12 months</time_frame>
    <description>Intraocular pressure will be measured by non contact tonometer as safety index</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Corneal Transplantation</condition>
  <arm_group>
    <arm_group_label>Single graft corneal transplantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Limbal transplantation combined with central penetrating keratoplasty from single donors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual graft corneal transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Limbal transplantation combined with central penetrating keratoplasty from different donors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Limbal transplantation combined with central penetrating keratoplasty</intervention_name>
    <description>Limbal transplantation combined with central penetrating keratoplasty with single donor cornea</description>
    <arm_group_label>Single graft corneal transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Limbal transplantation combined with central penetrating keratoplasty</intervention_name>
    <description>Limbal transplantation combined with central penetrating keratoplasty with mixed component cornea</description>
    <arm_group_label>Dual graft corneal transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Central corneal opacity involving full layer&#xD;
&#xD;
          -  Corneal neovascularization in two or more quadrants&#xD;
&#xD;
          -  Patients must be willing and able to return for scheduled follow-up examinations for&#xD;
             12 months after surgery&#xD;
&#xD;
          -  Ages：18 -70 Years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Central corneal opacity not involving the endothelial layer&#xD;
&#xD;
          -  Less than two quadrants of corneal neovascularization&#xD;
&#xD;
          -  History of Stevens-Johnson syndrome or Sjogren's syndrome&#xD;
&#xD;
          -  Severe eyelid and conjunctival scar&#xD;
&#xD;
          -  Loss of vision in contralateral eye&#xD;
&#xD;
          -  Pregnant and lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ting Huang, MD, PHD</last_name>
    <phone>86-13552338050</phone>
    <email>qingerdong@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Jin</last_name>
      <phone>86-20-87334687</phone>
      <email>lingjin41@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ting Huang, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2020</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High-risk corneal transplantation</keyword>
  <keyword>Penetrating keratoplasty</keyword>
  <keyword>Limbal transplantation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

